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Abstract 
Purpose 
Chronic pelvic pain (CPP) in the presence of dilated and refluxing pelvic veins is often 
described as pelvic congestion syndrome (PCS), although the causal relationship 
between pelvic vein incompetence and CPP has not been established. Percutaneous 
embolization is the principal treatment for PCS, with high success rates cited. Our 
objective was to systematically and critically review the effectiveness of embolization 
of incompetent pelvic veins. 
Materials and Methods 
A comprehensive search strategy encompassing various terms for pelvic congestion, 
pelvic pain and embolization was deployed in 17 bibliographic databases, with no 
restriction on study design. Methodological quality was assessed. The quality and 
heterogeneity generally precluded meta-analysis. Results were tabulated and described 
narratively.  
Results 
21 prospective case series and one poor quality randomized trial of embolization 
(involving 1308 women) were identified. Early substantial relief from pain was 
observed in approximately 75% of women undergoing embolization, which generally 
increased over time and was sustained. Where pain was measured on a visual analogue 
scale, statistically significant reductions following treatment were observed in all 
studies. Re-intervention rates were generally low. There were few data on the impact on 
menstruation, ovarian reserve or fertility, but no concerns were noted. Transient pain 
was common following foam embolization, whilst there was a <2% risk of coil 
migration. 
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Conclusions 
Embolization appears to provide symptomatic relief of chronic pelvic pain in the 
majority of women and is safe, although the quality of the evidence is low.  
Introduction 
Pelvic congestion syndrome (PCS) is described as chronic pelvic pain arising from 
dilated and refluxing incompetent pelvic veins. The diagnosis is based on patient 
reported symptoms, clinical examination, anatomical features, and venographic 
findings. There are no generally accepted, well-defined clinical criteria for the diagnosis 
of PCS, reflecting the residual uncertainty that there is a causal relationship between 
pelvic vein incompetence (PVI) and chronic pelvic pain (CPP).  
Elimination of the blood flow is a recognized strategy for treating incompetent veins. 
This can be achieved surgically, by ligation of a vein or since the early 1990s, via 
percutaneous introduction of an embolic agent upstream downstream of the dilated or 
refluxing veins.(1) Once the incompetent vein is occluded, blood is diverted via other 
veins, and in time, new vessels can form in the place of the original, although in theory 
these too could become incompetent. Whether recurrence of symptoms is a result of 
failure of the original embolization, or due to collateral or recanalized veins diverting 
the flow to the internal iliac vein (IIV) or elsewhere, , or through untreated or de novo 
varices, is unclear. 
The objective of this systematic review of the literature was to assess the effectiveness 
of percutaneous embolization of incompetent pelvic veins in reducing CPP in women. 
Secondary objectives were to assess radiological features, impact on fertility and 
adverse events.  
Materials and methods 
The systematic review was conducted based on a protocol developed prior to 
commencing the review and it has also been registered with the PROSPERO database. 
Ethics approval was not needed as no patients or patient identifiable data were involved. 
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Search strategy  
A comprehensive search strategy was developed. This was used in the following 
bibliographic databases: Web of Knowledge, British Nursing Index, CINAHL, 
Cochrane Library, DARE, Embase, MEDION, Medline and Web of Science. The 
foreign databases, AIM, IMEMR, IMSEAR, LILACS, PAHO, Popline, SciELO and 
WPRIM held on the World Health Organisation portal were also searched, from 
database inception to November 2013. Bibliographies of all relevant primary articles 
and reviews were hand searched to identify articles missed by the electronic searches. 
No language or study design restrictions were applied in the searching phase. 
Search terms for the condition included pelvic pain, pelvic congestion, pelvic or ovarian 
vein, incompetence or reflux, and variations of these as keywords and text. Search terms 
for the intervention included treatment, endovascular therapy, interventional radiology, 
embolization, sclerotherapy, ligation or occlusion, and variations of these as keywords 
and text. Wild card characters were used to capture alternative spellings and stems of 
words. The condition and treatments terms were each combined using the “or” term to 
broaden the search and the two components combined using the “and” function. See 
Supplementary Appendix 1. 
 
Study selection and data extraction  
Studies were selected for inclusion in the review in a three-step process (see Figure 1) if 
they fulfilled the following criteria:  
1. Population: Women with a clinical diagnosis of PCS and/or radiological 
diagnosis of PVI, with or without CPP. No restriction was placed on any 
previous treatment, age of the participants, duration of symptoms, co-morbidity 
(including co-presence of endometriosis or other gynecological cause) or 
severity of the complaint in selection of the studies or on the method of 
identification of the pelvic varices to be embolized. 
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2. Interventions: Coil embolization or sclerotherapy of pelvic veins, using any 
method. 
3. Outcomes: Studies reporting subjective assessment of pain or improvement in 
pain symptoms. 
4. Study design: Ideally, only reports of well designed, randomized controlled 
trials would be included, but preliminary searching indicated that these would 
be scarce. Primary reports of observational studies were therefore included, but 
restricted to those where participants were recruited prospectively. Case reports 
or small series with fewer than 6 participants were excluded. Where it was 
ambiguous as to whether the data was collected prospectively or 
retrospectively, a judgement was made based on the timeframe of the follow-
up assessments. Where participants were reassessed at particular time-points, it 
was accepted that they were recruited into the study prospectively. If the 
duration of follow-up was reported as a wide time frame, it was assumed that 
participants had been identified retrospectively and the follow-up was a cross-
sectional survey, therefore were excluded. 
Methodological quality assessment  
All studies selected for inclusion were assessed for their methodological quality in 
duplicate. For any eligible randomized trials, the Cochrane Collaboration risk of bias 
tool was used.(2) There are no universally accepted quality criteria and reporting 
standard for case series, as systematic reviews usually tend to exclude studies of this 
design, and there are no reporting standards. The quality of case series was assessed 
using criteria adapted from a published checklist.(3),  
Data synthesis 
Standard meta-analytical methods were used to estimate the overall proportion with a 
symptomatic improvement following embolization, using the proportions reported in 
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individual studies under both fixed and random effects assumptions. Plots were 
generated in MedCalc software (version 14.10.2. Ostend, Belgium). For other 
outcomes, studies were extracted in duplicate, tabulated and described narratively. 
Results 
Studies selection for the review 
A total of 2858 citations were identified through the electronic bibliographic database 
searches. Of these 2718 were excluded after reading of titles and abstracts, mainly 
because they referred to varicose veins of the lower limbs. From 140 citations whose 
full papers were retrieved, further exclusions were made:  seven studies investigated 
pelvic vein ligation, three studies were considered retrospective but reported on medium 
to long term outcomes, so were considered for this outcome, (4-6) and two studies, with 
a total of 37 women, although prospective in design, reported only on technical success 
and complications.(7, 8) This left 22 studies,(5, 9-29) reporting on 1308 women. A 
summary of the characteristics of the included studies is given in Table 1. 
Description of study characteristics 
The mean age of the study population was reported in 20 of the studies (5, 9-16, 18-23, 
25-29), and ranged between 32 and 51 years,.. Sixteen studies reported the reproductive 
status of the treated women in some format, (9-12, 14, 18-23, 25-29) usually as the 
mean parity, which ranged from 0.9 to 3.5. See Supplementary Table S1. There was no 
consistent reporting of any other demographic data e.g. body mass index, history and 
duration of symptoms.  
Bilateral embolization was conducted on 478 women, whilst 384 had only left-sided 
embolization, six only right-sided embolization, whilst for 440 women it was unclear. 
The total number of veins embolized and number or proportion of women who had 
either ovarian or internal iliac vein embolized is indeterminable. One of the larger series 
of 218 women (23), reported the distribution of the 526 veins treated as 27% right IIV, 
23% left IIV, 7% right OV and 32% left OV, but the degree of multiple vein 
embolization could not be extracted from the study report. 
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Embolization of pelvic veins was achieved using a sclerosant in 229 women, by use of 
metal coils (stainless steel or platinum) in 660 women and a combination of both in 405, 
with the method unclear in the remaining 13 women. The sclerosant used varied 
considerably and included 1-3% sodium tetradecyl sulphate, (12, 15, 22, 24) 2-3% 
aetoxisclerol (17, 20, 25, 27) or enbucrilate.(9, 28) There was no apparent trend towards 
or away from using either technique, either over time or between countries. 
Quality assessment 
There were 20 case series included in the review, see Supplementary Tables, Table S2 
with one further study being unable to be reliably assessed due to uncertainty after 
translation.(24) Whilst the aims and embolization techniques were clearly stated, a third 
did not clearly describe the intended outcome measures and how they were to be 
collected. Although we sought only prospective trials, it was still not clear in 40% that 
consecutive patients were included: this was reinforced by poor descriptions of the 
criteria with which women were referred for venography and inadequate reporting of 
losses to follow-up.  
The sole randomized trial was likely to be subject to selection, performance, 
measurement and attrition biases and was deemed of low internal validity. 
Symptomatic Improvement 
Subjective symptom relief was reported on ordinal scales of complete, moderate/ partial 
or no relief of CPP symptoms in six studies.(9-12, 24, 28) Early reporting of complete 
symptom relief, less than two months, ranged from 33% (24) to 80% (12) of study 
participants. )Pooling rates of complete, excellent or moderate improvement from these 
studies gave an overall improvement rate of 75% (95%CI 64 to 85%, I2 statistic 42%) at 
4-8 weeks post-procedure. See Figure 2. 
Few studies reported symptoms at two time-points. Van der Vleuten et al assessed all 
women twice and found 67% of women had moderate or obvious improvement at two 
months post-operatively, which increased to 76% at an average of 18 months (+/- 12 
months) later.(10) Other studies report 85% of women had some symptom improvement 
at 6 months (17, 25), which again increased to 95% after 12 months in the smaller study 
(Tropeano et al). At an average of 45 months of follow-up, relief rates of over 80% 
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were reported by two studies (16, 21) but sustained relief in only 47% in a third 
study.(26) 
Studies reported treatment failures either as residual symptoms, unsatisfactory 
improvement or as the number of repeat embolizations performed. In a larger study, 22 
of 193 of women (11%) had mild or moderate residual symptoms at 6 weeks (23), 
whilst another reported only 2.2% found their improvement unsatisfactory.(24) Re-
intervention by 3-6 months due to unresolved symptoms was reported in 5.7% of 
women by D'Archambeau et al (5), lower than the 15% at 3 months cited by Tropeano 
et al.(25)  
No study reported quality of life using a generic instrument. Chung and Huh et al 
deployed a social readjustment rating scale (30) to compare stress between women who 
had embolization or hysterectomy but found no significant differences.(14) 
Pain Scores 
Nine studies report on pelvic pain scores from 0-10cm visual analogue scales, although 
at varying time-points after embolization.(13, 14, 16, 18, 19, 22, 25, 26, 29) In all cases, 
the pain score reduces significantly from a baseline and were generally sustained in 
those trials. See Figure 3. 
Five studies undertook paired t-tests of pain scores before and after embolization and 
reported the reductions as being statistically significant, with sufficient data that this 
could be verified by the reviewers.(16, 18, 22, 26, 29) There were insufficient studies 
with all necessary data to perform a meta-analysis. See Supplementary Tables, Table S3.  
Several studies reported on different pain symptoms. Kim et al noted statistically 
significant score reductions in pain on standing, lying down, dyspareunia and 
dysmenorrhea, as well as the amount of pain relief required, (16) whilst Venbrux et al 
also observed similar reductions in all symptoms except dysmenorrhea.(13) Gandini et 
al reported statistically significant reductions in dyspareunia and dysmenorrhea (22); 
Creton et al also considered pain at the site of pelvic varices occurring specifically 
before or during menstruation, which decreased from a mean of 6.0 to 1.7 at 45 days 
post embolization and remained low.(19) Van der Vleuten et al reported on the widest 
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range of symptoms, observing statistically significant improvements in scores at 2 
months and an average of 18 months (SD 12 months) for dysmenorrhea, dyspareunia, 
worsening of symptoms with walking, standing or sitting, varicose veins and pain in 
varicose veins.(28)  
Impact on pelvic vein reflux and diameter. 
Only two studies quantified the diameter of the pelvic veins before and after the 
procedure. One study measured the mean diameter of varices in supine patients, 
decreasing from 6.3 mm to 4.4mm and 4.5mm to 3.1mm for the left and right OV 
respectively, both statistically significant reductions.(15) In another study, left and right 
OV diameters reduced from a mean of 6.9mm (SD 2.1) and 5.1mm (SD1.4) to less than 
4.5mm on both sides in all cases.(27) Pieri et al noted that symptoms persisted in 
women in whom, although their OV varicosities decreased in diameter from pre-
procedure measurements, remained over 5mm at rest.(15) 
Ratnam et al was able to perform a repeat transvaginal ultrasound (TVUS) at 6-8 weeks 
in 193 patients, observing residual mild reflux in 16 (8.3%).(23)  Nine women had a 
second procedure dictated by the ultrasound: six patients due to moderate persistent 
reflux and three because of new reflux. Tropeano et al also repeated the TVUS at 3, 6 
and 12 months and observed an absence of reflux and reduced (<5mm) pelvic vein 
diameter in 17 of 20 (85%) women.(25) The remaining 3 women who showed 
recurrence or persistent left sided reflux, were also those who did not report a 
symptomatic improvement, and had a successful repeat procedure performed at 4-5 
months and were reported as symptom free after a median follow-up of 15 months. 
Impact on future fertility, menstruation and ovarian reserve 
Venbrux et al captured information on menstruation between 6 and 24 hours post-
procedure, in 24 of 56 participants, finding no significant difference in the interval or 
length of menstruation compared to before the embolization.(13) Kim et al measured 
follicular stimulating hormone, estradiol, and luteinizing hormone at baseline, six and 
12 months and reported no statistically significant differences before and after the 
procedure.(16) 
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No study explicitly included or excluded women based on their desire for a future 
pregnancy, nor specifically mentioned active follow-up of future pregnancies. 
Therefore, reports of pregnancies are likely not to have been systematically collected. 
Three studies report six successful pregnancies.(9, 13, 16)  
Adverse events of embolization 
Six studies did not report any adverse events in their population, although it is not clear 
whether this equates to technical success in all cases. Of the remaining 938 women, in 
total there were 10 cases of vein perforation causing extra-vascular leakage of contrast 
media during the insertion of coils. Transient pain following the embolization was 
reported in between 8% and 100% of cases and only appeared to occur in the studies 
using sclerotherapy, with or without coils. One large study of 239 women described 
early adverse symptoms as a “post-embolization syndrome”, reporting that 129 (54%) 
had transient gluteal or lumbar pain, 61 (26%) general achiness, 30 (12%) transient 
fever (≥38°C) and 21 (9%) had mechanical superficial phlebitis at the point of venous 
access in the arm. 
Coil migration after placement was reported in 11 cases, being displaced to the lung in 
eight cases, the renal vein in two cases and one report of coil protrusion into the femoral 
vein. In all cases, the coil was retrieved by a catheterized snare without any lasting harm 
to the woman. 
Discussion 
This systematic review of embolization for PVI found no high quality studies, so all 
estimates of effectiveness are derived from presumed prospective case series reporting 
on 1308 women, the majority of whom were of reproductive age and parous.  
Early substantial relief from pain symptoms was observed in approximately 75% of 162 
women in six case series, which generally increased over time and was sustained. 
Where pain was measured on a visual analogue scale, statistically significant reductions 
following treatment were observed in all studies. Re-intervention rates were generally 
low. Where measured, embolization reduced the diameter of dilated veins to a 
significant degree, with minimal residual reflux. 
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There was little data on menstruation, ovarian reserve or fertility, but no concerns were 
noted. Transient pain was a common occurrence following foam embolization, whilst 
there was a <2% risk of coil migration. 
The review followed a registered protocol and focused on a clear question for the 
assessment of effectiveness. The comprehensive search strategy is the broadest ever 
applied in a review of PCS. All outcomes identified a priori were reported upon to the 
extent that data were available. The embolic techniques employed were generally well 
described and follow-up data was available for the majority of participants. 
The most significant limitation, which prevents firm conclusions being drawn from the 
data and recommendations being made, is the quality of the studies identified. There is 
only one randomized controlled trial of embolization in the literature, with 
hysterectomy as a comparison, which was in itself not free of potential biases. The 
majority of the studies were relatively small case series, with the inherent high risk of 
bias, with no comparative group and frequently ill-defined inclusion criteria. In 
comparison to other reviews in this area, we attempted to restrict the studies included to 
those where participants were prospectively enrolled, in order to reduce selection bias, 
unlike other reviews.(31). However, in some studies it was impossible to be completely 
certain, from the methodology used, that included participants were not retrospectively 
identified from medical records.  
The effect of embolization on pain was generally described either in terms of 
symptomatic improvement or as pain scores, reducing the amount of information 
available for either outcome. We cannot be certain these outcomes were not collected 
across all studies but not reported if they failed to show statistical significance or 
consistent results. We performed a meta-analysis to get a pooled estimate of 
improvement rates, but may be criticized for doing so using such low quality data.  Few 
studies sought pain data on individual pain symptoms, such as dyspareunia or pain on 
standing, preventing reflection on whether embolization reduces specific symptoms 
thought to be particularly indicative of pelvic vein congestion.  
The pooled estimate of moderate to complete symptomatic improvement following 
embolization is consistent with previous limited reviews, as are the rates of coil 
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migration, although these too draw upon low quality case series.  (31, 32) Technical 
success is high, although dependent on pelvic anatomy, and has been widely adopted 
around the world. Few studies addressed the impact on menstruation and fertility. This 
contrasts starkly with uterine artery embolization for the uterine fibroids, where there is 
considerable debate regarding the impact on ovarian function and pregnancy rates.(33, 
34)  
Whilst the data appears supportive, the quality of evidence is poor. Under the GRADE 
criteria, the methodological quality is very low and there is no direct comparative 
evidence against no embolization.(35) Some reflection on the only randomized 
controlled trial is warranted. The study population excluded those whose pain could be 
attributable to organic pathology or who responded to medroxyprogesterone, and who 
did not wish to retain their uterus and ovaries. The 118 patients were randomized to 
either embolization or hysterectomy with bilateral oophorectomy, plus hormone 
replacement therapy, or hysterectomy with unilateral oophorectomy, on the 
predominantly congested side.(14) The study reported that the embolization group and 
the hysterectomy with bilateral oophorectomy group had statistically significant 
improvement in pain reported on a visual analogues scale at 3, 6 and 12 months, 
whereas those with only unilateral oophorectomy did not, but these assertions have not 
be replicated. Furthermore, the method of randomization was unclear and there were 
substantial post-randomization exclusions, which undermine the credibility of the trial 
results.  
We were unable to investigate heterogeneity of results across studies other than for the 
outcome of moderate to complete symptomatic improvement, reported in 6 studies, 
where moderate heterogeneity was identified. This could arise from the embolization 
technique, the way in which the question of improvement was presented and 
categorized or from the population included in the study.  
The precision of the estimates for this outcome is moderate, due to the relatively small 
number of studies and participants per study, with a confidence interval of ±10% around 
the pooled rate of substantial symptomatic improvement of 75% in the short term. This 
would probably encompass a range of response rates that would be acceptable to 
women, given the low incidence of adverse events. However, we cannot be certain that 
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publication bias does not exist and that this results is not an overestimation of the true 
effect.  
If we can accept that embolization provides pain relief, despite the limitations of the 
literature, the next questions are whether particular presenting characteristics can predict 
a successful outcome, and what the optimal technique is. A retrospective case series of 
41 women access the relationship between technique (bilateral or unilateral), parity and 
location of varices (thigh or labial compared to pelvic) and clinical outcome.  There was 
no statistically significant predictor of a successful outcome amongst these variables, 
although a trend towards a higher rate of success in grand multiparous women was 
noted. No association between these variables and treatment failure was observed, but in 
both circumstances, it may just be that there are too few women to observe a small 
association.(4) 
No apparent trend for either metal coils or sclerosant has emerged. Stratification of the 
meta-analysis of symptomatic improvement by method is limited by the amount of data 
but seems to suggest the overall rate of substantial improvement is reflective of the 
studies using sclerosant at about 75%, whereas the two studies using solely coils had 
higher rates, at 89% and 100% respectively.(10, 11) No obvious differences between 
methods on the reduction in pain scores were seen. It may indeed be that the 
presentation of the varices and anatomy of the veins are the key determinants of 
successful elimination of reflux, with perhaps both methods being requiring for the most 
dilated veins. 
Complications of embolization appear to be limited to short-term pain and fever in a 
reasonable proportion of sclerosant cases, or an uncommon incidence of coil migration. 
Coil placement is a relatively straightforward procedure but may be subject to 
recanalization or development of collaterals, as has been observed in male 
varicocele.(36) Some radiologists prefer liquid sclerosants the perception being that a 
more extensive embolus is produced, and also due to their cost compared with metal 
coils.(4) 
Women should be counselled that the embolization, whilst apparently safe, may not 
provide complete relief of symptoms. There is scope for considerable further research 
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into the condition known as pelvic congestion syndrome, and in particular, an 
adequately powered randomized trial is essential to provide the necessary data on the 
effectiveness of embolization, but faces methodological challenges.
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Figure 1: Flow diagram showing the study selection process for the systematic review 
of embolization and sclerotherapy for reducing chronic pelvic pain 
Footnote: 
* Seven studies of OV ligation were identified in an initial scoping search. We made a 
decision after registration on the PROSPERO database to exclude studies of ligation 
from this review, as it is rarely performed in current practice now that the technically 
less demanding and lower risk option of percutaneous vein embolization is widely 
available. 
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Table 1 Characteristics and key outcomes of studies selected for inclusion in systematic review of effectiveness of embolization of pelvic 
vein incompetence 
Author, 
date, 
country 
Number Treatment Study type Outcomes, follow up 
period 
Key results 
Capasso  
1997 
Belgium 
 
19 OV vein glue, 
coil or 
combined 
embolization  
Prospective 
observational 
study  
Subjective assessment 
of pain relief within 4 
weeks. Trans-abdominal 
Doppler ultrasound at 5 
weeks. Average 15 
month follow up for 
recurrence. 
Early outcomes: 74% had improvements in pain 
symptoms (complete relief in 58%, partial in 16%). 
Improvement correlated with ultrasonographical 
evidence of complete thrombosis of varices. 
Dyspareunia (n=5) persisted. N=5 with persistent 
pain had re-intervention. 2 venous perforations that 
resolved. 
Tarazov  
1997 
Russia 
6 OV coil 
embolization. 
Not stated Subjective reporting of 
symptom Improvement, 
follow-up duration 1-4 
Complete alleviation of CPP in all women within 4 
weeks. Improved menstrual symptoms I 2 women 
with dysmenorrhea. No serious complications. 
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years. 
Cordts  
1998  
USA 
9 OV coil 
embolization. 
Consecutive 
case series 
Numerical rating scale 
of symptom relief, mean 
follow-up 13 months 
8 women (88.9%) had >80% immediate symptom 
relief. Two women had a mild or moderate return of 
the symptoms at 6 and 22 months respectively. One 
lower lobe coil pulmonary embolus. 
Scultetus  
2002 
USA 
15 
(treated 
with 
sclerothe
rapy) 
Sclerotherapy 
of varices 
alone or with 
excision of 
varices. 
 
Prospective 
observation 
study  
VAS of improvement. 
Mean follow-up 2.3 
years. 
12 had excellent improvement, 3 had moderate 
improvement. No deep vein thrombosis reported.  
Venbrux  
2002 
USA 
 
56 OV and 
subsequent 
IIV coil 
embolization 
Prospective 
observational 
study  
VAS for pain, menstrual 
cycle questionnaire at 3, 
6 and 12 months post 
procedure.  
Mean pain 7.8 at baseline decreased to 4.2 at 3-
months, 3.8 at 6 months, 2.7 at 12 months (p<0.001 
for all comparisons). No significant changes in cycle 
length.  
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Chung  
2003 
South 
Korea 
 
 
106, of 
whom 
52 
treated 
with 
emboliz
ation 
OV or IIV coil 
embolization, 
Hysterectomy 
with uni or 
bilateral 
oophorectomy  
Randomized 
control trial  
VAS at 3, 6, and 12 
months post-procedure, 
patient global 
impression of change. 
Statistically significant decrease from baseline and 
between embolization and hysterectomy groups at all 
time-points.   
Pieri  
2003 
Italy 
33 OV foam 
sclerotherapy 
Prospective 
observational 
study  
Subjective rating of 
various pain symptoms 
at 1 month. Clinical 
assessment and mean 
venous diameter by 
ultrasound at 6 months. 
Improvement in pain in 61%. Mean OV diameter at 
baseline right 4.5mm and left 6.3mm reduced to 3.10 
and 4.4mm respectively at follow-up. Seven patients 
had transient flank pain.  
Kim  127 OV Retrospectivel Visual analogue scale Mean pelvic pain at baseline 7.6 (SD 1.8) and 2.9 
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2006 
USA 
coil/sclerosant 
embolization, 
+/- subsequent 
IIV sclerosant 
embolization  
y identified 
women 
followed-up 
prospectively.  
and composite clinical 
assessment at 3 and 6 
months and annually 
thereafter.  
(SD 2.8) (p < 0.0001) and 80% had significant 
improvement at mean 45 months follow-up. All pain 
symptoms significantly improved. Two coil 
migrations. 
Leal 
Monedero  
2006 
Spain 
239 
 
Coil 
embolization 
+/- foam, of 
OV or IIV 
Observational 
study 
Clinical assessment at 6 
months post-procedure. 
Complete resolution of pain symptoms in 120/ 239 
(50.2%) and partial relief in 95/239 (36.8%). 
Superficial phlebitis at point of venous access in 21 
women. No coil migrations. 
 
Richardson  
2006 
Australia 
26 OV coil 
embolization, 
+/- foam. 
Prospective 
case series, 
with historical 
control group 
undergoing 
Visual analogue scale 
for pain symptoms and 
patient overall 
satisfaction. Mean 
follow-up 22±13 
No significant difference between groups in 
demographics and presenting symptoms. Coil group 
pain score statistically significantly reduced from 6.6 
(SD 1.9) to 4.0 (SD 2.8), from baseline. No 
statistically significant difference in pain reduction 
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OV ligation.  months. between ligation and embolization groups nor in 
overall satisfaction. No coil migration within 6 
weeks, one coil perforation detected at 5 months.  
Creton  
2007 
France 
 
24 OV or IIV coil 
embolization  
Prospective 
observational 
study  
VAS for dysmenorrhea, 
dyspareunia and venous 
pain (individually and 
total); clinical 
assessment at 45 days 
and 1,2 and 3 years 
follow up  
Statistically significant decreases in all three pain 
symptoms and improvements in clinical assessment 
maintained. One coil migration. 
Greiner  
2007 
France 
13 (of 
24 
emboliz
ed) 
Coil or glue or 
combined 
embolization 
of OV and 
IIV. 
Observational 
study 
(assumed 
prospective) 
Repeat TVUS at 1 and 6 
months, 1 and 4 years. 
Repeat clinical 
assessment and 
venography at 4 years.  
Complete resolution of symptoms in 10/13 and 
significant improvement in 3/13. No recurrence of 
PVI. 
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Kwon  
2007 
South 
Korea 
 
67 OV coil 
embolization  
Prospective 
study of 
outcome with 
baseline pain 
determined by 
telephone 
interview or 
medical note 
review 
Categorical pain 
severity scale. Mean 
follow up 45 months  
82% reported total or significant pain reduction. Two 
coil migrations.  
Gandini  
2008 
Italy 
 
38 OV foam 
sclerotherapy  
Described as 
retrospective 
but included 
all patients at 
3 defined 
time-points 
VAS for 4 pain 
symptoms at 1, 3, 6 and 
12 months follow up  
Mean VAS for CPP showed decrease from 7.8 (SD 
1.8) to 2.7(SD 2.8), from 4.9(SD 4.2) to 2.2(3.1) for 
menstrual pain, from 3.3(SD 3.7) to 1.5(SD 2.7) for 
dyspareunia and 3.5(SD 3.9) to 1.5(SD 3.0) for 
urinary urgency at 12 months, all statistically 
significant. 
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Ratnam  
2008 
UK 
218 Coil 
embolization 
of OV and IIV 
Prospective 
inclusion, 
retrospective 
data extraction 
from medical 
notes. 
Repeat TVUS at 6-8 
weeks 
Of 193 with follow-up, 16 had residual mild reflux, 6 
had marked reflux and 3 had new reflux.  
Two coil migrations, one misplacement, one case of 
perineal thrombophlebitis. 
Sukovatyk
h  
2008 
Russia 
59 Sclerotherapy Not stated Clinical examination, 
USS and self-reported 
quality of life  
Improvements (not defined) were classified as 
excellent in 32.6%, good in 46.1%, satisfactory in 
19.1% and unsatisfactory in 2.2% of the patients. 
Tropeano  
2008 
Italy 
20 Sclerotherapy 
of the OV  
Prospective 
observational 
study 
VAS for pain, menstrual 
cycle questionnaire and 
ultrasound at 3, 6 and 12 
months post procedure. 
 
Three women had repeat embolization after 3 months 
due to no change in symptoms and residual PVI on 
ultrasound. 17 (85%) achieved marked to complete 
relief until 6 months, with 2 describing a reduction in 
relief by 12 months, 
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 Median VAS pain scores decreased from at 8.0 
(range 6.0 to 10.0) at baseline to 2.0 (1.0 – 5.0), 2.5 
(1.5 - 5.0), and 3.0 (2.0 – 6.0) at 3, 6 and 12 months 
respectively, all statistical significantly reductions 
(p<.001).  
Asciutto  
2009 
Germany 
 
35 (26 
also had 
concurre
nt VV 
surgery) 
OV, IIV or 
both  with coil 
embolization  
Prospective 
observational 
study  
VAS of pain at 1,2,3 
years of follow up  
VAS scores for isolated OVI: baseline mean 5.2 (SD 
3.5) and 1.2 (SD 0.9) at 3 years; p<0.0001, non-
statistically significant reduction for combined OVI 
and IIV or isolated IIV alone. At mean follow-up 45 
months, overall 47% had sustained improvement. 3 
venous perforations that resolved. 
D’Archam
beau  
2010 
Belgium 
193 (130 
had PVI) 
Coil 
embolization 
of OV 
Prospective 
observational 
study 
Symptom rating on 
VAS before procedure 
and at 1 year. 
11 (5.7%) were re-embolized between 3 months and 
6 years. 91/102 (89.2%) patients with PCS symptoms 
reported improvement in symptoms on VAS. 
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Tinelli  
2012 
Italy 
28 OV foam 
sclerotherapy  
Not stated but 
follow-up at 
specific time-
points. 
VAS for pain, clinical 
examination and USS at 
10 days, 1 and 6 months 
post procedure.  
At 1 month, 6 (21%) reported PVI symptoms, which 
resolved by 6 months. Reduction in varicosity size 
from  6.9mm (SD 2.1mm) on left and 5.1mm 
(SD1.4mm) on right to <4.5mm in all embolized 
veins. 100% technical success with no adverse 
events beyond minor analgesics needs in 6 (21%) 
patients. 
van der 
Vleuten  
2012 
Netherland
s 
21 who 
responde
d 
follow-
up 
survey 
Sclerotherapy 
of OV. 
Prospective 
observational 
study  
5 point ordinal scale of 
8 pain symptoms and 
pelvic varices and 
hemorrhoids, and global 
impression of change. 
14 (66.7%) and 16 (76.2%) women had moderate or 
obvious improvement or no symptoms, at 2 months 
and cross sectional follow-up at mean 18 ±122 
months survey, respectively. All pain symptoms 
except backache or urinary symptoms showed 
statistically significant improvements. Nine (42.9%) 
women had a second embolization. 
Meneses  10 Combined OV Prospective Venous clinical severity Significant decrease in pain from 8.2 at baseline to 
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2013 
Chile 
and/or IIV 
embolization, 
using 
sclerosant and 
coil. 
observational 
study 
score (VCSS) and VAS 
for pain at 3 months 
follow-up. 
4.0 at 3 months (p<0.001). Significant decrease in 
VVCS from 8.4 at baseline to 3.6 at 3 months 
follow-up (P<0.001). No VV recurrence by 6 
months. 
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Figure 1 Meta-analysis of rates of complete, excellent or moderate (combined) 
improvement 4-8 weeks following embolization  
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Figure 2 Time course of pain scores following embolization for pelvic vein 
incompetence 
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Table S1 Characteristics of studies selected for inclusion in systematic review of effectiveness of embolization of pelvic vein incompetence 
Author, date, 
country 
Number Patient group Treatment Study type Outcomes, 
follow up 
period 
Key results 
Capasso  
1997 
Belgium 
 
19 Women with 
clinical and 
ultrasonographic
al or 
radiological 
evidence of PVI. 
OV vein glue 
(n=24), coil (n=2) 
or combined 
(n=4) 
embolization; left 
OV only n=13, 
bilateral n=6.   
Prospective 
observational 
study  
Subjective 
assessment of 
pain relief 
within 4 weeks. 
Trans-
abdominal 
Doppler 
ultrasound at 5 
weeks. Average 
15 month follow 
Early outcomes: 74% 
had improvements in 
pain symptoms 
(complete relief in 
58%, partial in 16%). 
Improvement 
correlated with 
ultrasonographical 
evidence of complete 
thrombosis of varices. 
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up for 
recurrence. 
Dyspareunia (n=5) 
persisted. N=5 with 
persistent pain had re-
intervention. 2 venous 
perforations that 
resolved. 
Tarazov  
1997 
Russia 
6 Women with 
clinical and 
radiological 
evidence of PVI 
Bilateral n=1 or 
left unilateral n=5 
OV coil 
embolization. 
Not stated Subjective 
reporting of 
symptom 
Improvement, 
follow-up 
duration 1-4 
years. 
Complete alleviation 
of CPP in all women 
within 4 weeks. 
Improved menstrual 
symptoms I 2 women 
with dysmenorrhea. 
No serious 
complications. 
Cordts  9 Women with Bilateral n=4 or Consecutive Numerical 8 women (88.9%) had 
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1998  
USA 
clinical and 
ultrasonographic 
and/or 
radiological 
evidence of PVI. 
left unilateral n=4 
OV coil 
embolization. 
case series rating scale of 
symptom relief, 
mean follow-up 
13 months 
>80% immediate 
symptom relief. Two 
women had a mild or 
moderate return of the 
symptoms at 6 and 22 
months respectively. 
One lower lobe coil 
pulmonary embolus. 
Scultetus  
2002 
USA 
15 
(treated 
with 
sclerothe
rapy) 
Women with 
“mild” 
discomfort, 
small varies and 
mild reflux by 
Doppler 
ultrasound. 
Sclerotherapy of 
varices alone or 
with excision of 
varices. 
 
Prospective 
observation 
study  
VAS of 
improvement. 
Mean follow-up 
2.3 years. 
12 had excellent 
improvement, 3 had 
moderate 
improvement. No deep 
vein thrombosis 
reported.  
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Venbrux  
2002 
USA 
 
56 Women with 
clinical and 
ultrasonographic 
and/or 
radiological 
evidence of PVI. 
Bilateral OV 
(100%) and 
subsequent IIV 
(77%) coil 
embolization 
 
Prospective 
observational 
study  
VAS for pain, 
menstrual cycle 
questionnaire at 
3, 6 and 12 
months post 
procedure.  
Mean pain 7.8 at 
baseline decreased to 
4.2 at 3-months, 3.8 at 
6 months, 2.7 at 12 
months (p<0.001 for 
all comparisons). No 
significant changes in 
cycle length.  
Chung  
2003 
South Korea 
 
 
106, of 
whom 52 
treated 
with 
emboliza
tion 
Pre-menopausal 
women with 
idiopathic CPP 
and a score of 
≥5 on a 
modified 
venography 
a) OV or IIV coil 
embolization 
(n=52) b) 
Hysterectomy 
with bilateral 
oophorectomy  
(n=27) c) 
Randomized 
control trial  
VAS at 3, 6, and 
12 months post-
procedure, 
patient global 
impression of 
change. 
Statistically significant 
decrease from baseline 
and between 
embolization and 
hysterectomy groups 
at all time-points.   
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scale, refractory 
to MPA.  
Hysterectomy 
with unilateral 
oophorectomy 
(n=27)  
Pieri  
2003 
Italy 
33 Women with 
clinical and 
ultrasonographic
al evidence of 
PVI. 
 
OV foam 
sclerotherapy 
(64% bilaterally) 
Prospective 
observational 
study  
Subjective 
rating of various 
pain symptoms 
at 1 month. 
Clinical 
assessment and 
mean venous 
diameter by 
ultrasound at 6 
months. 
Improvement in pain 
in 61%. Mean OV 
diameter at baseline 
right 4.5mm and left 
6.3mm reduced to 3.10 
and 4.4mm 
respectively at follow-
up. Seven patients had 
transient flank pain.  
Kim  127 Women with Bilateral (85%) or Retrospectivel Visual analogue Mean pelvic pain at 
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2006 
USA 
clinical and 
radiological 
evidence of PVI, 
including 25 
with 
hysterectomy.   
unilateral (15%) 
OV 
coil/sclerosant 
embolization, 
with 85% having 
subsequent IIV 
sclerosant 
embolization  
y identified 
women 
followed-up 
prospectively.  
scale and 
composite 
clinical 
assessment at 3 
and 6 months 
and annually 
thereafter.  
baseline 7.6 (SD 1.8) 
and 2.9 (SD 2.8) (p < 
0.0001) and 80% had 
significant 
improvement at mean 
45 months follow-up. 
All pain symptoms 
significantly 
improved. Two coil 
migrations. 
Leal Monedero  
2006 
Spain 
239 
 
Women with 
clinical and 
radiological 
evidence of PVI 
(with or without 
Coil embolization 
with or without 
foam, of OV or 
IIV, with VV 
surgery where 
Observational 
study (unclear 
whether 
prospective or 
retrospective) 
Clinical 
assessment at 6 
months post-
procedure. 
Complete resolution of 
pain symptoms in 120/ 
239 (50.2%) and 
partial relief in 95/239 
(36.8%). Superficial 
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CPP) and lower 
limb VV 
indicated s phlebitis at point of 
venous access in 21 
women. No coil 
migrations. 
 
Richardson  
2006 
Australia 
26 Women with 
CPP and 
ultrasonographic 
evidence of PVI. 
Coil 
embolization, 
with or without 
foam, of OV. 
Case series, 
with historical 
control group 
undergoing 
OV ligation. 
Patient 
information 
suggests 
prospective.  
Visual analogue 
scale for pain 
symptoms and 
patient overall 
satisfaction. 
Mean follow-up 
22±13 months. 
No significant 
difference between 
groups in 
demographics and 
presenting symptoms. 
Coil group pain score 
statistically 
significantly reduced 
from 6.6 (SD 1.9) to 
4.0 (SD 2.8), from 
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baseline. No 
statistically significant 
difference in pain 
reduction between 
ligation and 
embolization groups 
nor in overall 
satisfaction. No coil 
migration within 6 
weeks, one coil 
perforation detected at 
5 months.  
Creton  
2007 
France 
24 Pre-menopausal 
women with 
dysmenorrhea/ 
OV or IIV coil 
embolization  
Prospective 
observational 
study  
VAS for 
dysmenorrhea, 
dyspareunia and 
Statistically significant 
decreases in all three 
pain symptoms and 
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 dyspareunia and 
radiological 
evidence of PVI. 
venous pain 
(individually 
and total); 
clinical 
assessment at 45 
days and 1,2 and 
3 years follow 
up  
improvements in 
clinical assessment 
maintained. One coil 
migration. 
Greiner  
2007 
France 
13 (of 24 
embolize
d) 
Women with 
clinical and 
ultrasonographic
al evidence of 
PVI with CPP 
and lower limb 
VV. 
Bilateral and 
unilateral coil or 
glue or combined 
embolization of 
OV and IIV. 
Observational 
study 
(assumed 
prospective) 
Repeat TVUS at 
1 and 6 months, 
1 and 4 years. 
Repeat clinical 
assessment and 
venography at 4 
years.  
Complete resolution of 
symptoms in 10/13 
and significant 
improvement in 3/13. 
No recurrence of PVI. 
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Kwon  
2007 
South Korea 
 
67 Women with 
clinical and 
radiological 
evidence of PVI 
OV coil 
embolization 
(96% left OV 
only) 
Prospective 
study of 
outcome with 
baseline pain 
determined by 
telephone 
interview or 
medical note 
review 
Categorical pain 
severity scale. 
Mean follow up 
45 months  
82% reported total or 
significant pain 
reduction. Two coil 
migrations.  
Gandini  
2008 
Italy 
 
38 Women with 
CPP and 
ultrasonographic 
evidence of PVI. 
Bilateral OV 
foam 
sclerotherapy (3% 
STSF)  
Described as 
retrospective 
but included 
all patients at 3 
defined time-
points 
VAS for 4 pain 
symptoms at 1, 
3, 6 and 12 
months follow 
up  
Mean VAS for CPP 
showed decrease from 
7.8 (SD 1.8) to 2.7(SD 
2.8), from 4.9(SD 4.2) 
to 2.2(3.1) for 
menstrual pain, from 
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3.3(SD 3.7) to 1.5(SD 
2.7) for dyspareunia 
and 3.5(SD 3.9) to 
1.5(SD 3.0) for urinary 
urgency at 12 months, 
all statistically 
significant. 
Ratnam  
2008 
UK 
218 Women with 
ultrasonographic
al evidence of 
PVI and veins 
communicating 
with lower limb  
VV 
Bilateral and 
unilateral coil 
embolization of 
OV and IIV, with 
VV surgery 
deferred to >8 
weeks post 
procedure. 
Prospective 
inclusion, 
retrospective 
data extraction 
from medical 
notes. 
Repeat TVUS at 
6-8 weeks 
Of 193 with follow-up, 
16 had residual mild 
reflux, 6 had marked 
reflux and 3 had new 
reflux.  
Two coil migrations, 
one misplacement, one 
case of perineal 
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thrombophlebitis. 
Sukovatykh  
2008 
Russia 
59 Women with 
clinical and 
ultrasonographic 
and/or 
radiological 
evidence of PVI 
Sclerotherapy Not stated Clinical 
examination, 
USS and self-
reported quality 
of life  
Improvements (not 
defined) were 
classified as excellent 
in 32.6%, good in 
46.1%, satisfactory in 
19.1% and 
unsatisfactory in 2.2% 
of the patients. 
Tropeano  
2008 
Italy 
20 Women with 
CPP and 
ultrasonographic 
evidence of PVI, 
with no pelvic 
pathology seen 
Sclerotherapy of 
the OV (15% 
bilateral) 
Prospective 
observational 
study 
VAS for pain, 
menstrual cycle 
questionnaire 
and ultrasound 
at 3, 6 and 12 
months post 
Three women had 
repeat embolization 
after 3 months due to 
no change in 
symptoms and residual 
PVI on ultrasound. 17 
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at laparoscopy 
and 
embolization 
possible 
anatomically. 
procedure. 
 
 
(85%) achieved 
marked to complete 
relief until 6 months, 
with 2 describing a 
reduction in relief by 
12 months, 
Median VAS pain 
scores decreased from 
at 8.0 (range 6.0 to 
10.0) at baseline to 2.0 
(1.0 – 5.0), 2.5 (1.5 - 
5.0), and 3.0 (2.0 – 
6.0) at 3, 6 and 12 
months respectively, 
all statistical 
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significantly 
reductions (p<.001).  
Asciutto  
2009 
Germany 
 
35 (26 
also had 
concurre
nt VV 
surgery) 
Women with 
clinical and 
radiological 
evidence of PVI. 
OV (n=28), 
IIV(n=5) or both 
(n=2) with coil 
embolization  
Prospective 
observational 
study  
VAS of pain at 
1,2,3 years of 
follow up  
VAS scores for 
isolated OVI: baseline 
mean 5.2 (SD 3.5) and 
1.2 (SD 0.9) at 3 
years; p<0.0001, non-
statistically significant 
reduction for 
combined OVI and 
IIV or isolated IIV 
alone. At mean follow-
up 45 months, overall 
47% had sustained 
improvement. 3 
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venous perforations 
that resolved. 
D’Archambeau  
2010 
Belgium 
193 (130 
had PVI) 
Women with 
clinical and 
radiological 
evidence of PVI. 
Bilateral (4.7%) 
or unilateral coil 
(94.3% left, 1% 
right) coil 
embolization of 
OV 
Prospective 
observational 
study 
Symptom rating 
on VAS before 
procedure and at 
1 year. 
11 (5.7%) were re-
embolized between 3 
months and 6 years. 
91/102 (89.2%) 
patients with PCS 
symptoms reported 
improvement in 
symptoms on VAS. 
Tinelli  
2012 
Italy 
28 Women with 
ultrasonographic 
and radiological 
evidence of PVI 
OV foam 
sclerotherapy 
(29% bilaterally) 
Not stated but 
follow-up at 
specific time-
points. 
VAS for pain, 
clinical 
examination and 
USS at 10 days, 
1 and 6 months 
At 1 month, 6 (21%) 
reported PVI 
symptoms, which 
resolved by 6 months. 
Reduction in 
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post procedure.  varicosity size from  
6.9mm (SD 2.1mm) 
on left and 5.1mm 
(SD1.4mm) on right to 
<4.5mm in all 
embolized veins. 
100% technical 
success with no 
adverse events beyond 
minor analgesics needs 
in 6 (21%) patients. 
van der Vleuten  
2012 
Netherlands 
21 who 
responde
d follow-
up 
Women with 
CPP and 
radiological 
evidence of PVI 
Bilateral or 
unilateral 
sclerotherapy of 
OV. 
Prospective 
observation 
study for 2 
month follow-
5 point ordinal 
scale of 8 pain 
symptoms and 
pelvic varices 
14 (66.7%) and 16 
(76.2%) women had 
moderate or obvious 
improvement or no 
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survey with or without 
lower limb VV 
up, with cross 
sectional 
follow-up at 
mean 18 ±122 
months 
and 
hemorrhoids, 
and global 
impression of 
change. 
symptoms, at 2 months 
and at the survey, 
respectively. All pain 
symptoms except 
backache or urinary 
symptoms showed 
statistically significant 
improvements. Nine 
(42.9%) women had a 
second embolization. 
Meneses  
2013 
Chile 
10 Women 
undergoing 
repeat surgery 
for VV 
recurrence and 
Combined OV 
and/or IIV 
embolization, 
using sodium 
morrhuate 
Prospective 
observational 
study 
Venous clinical 
severity score 
(VCSS) and 
VAS for pain at 
3 months 
Significant decrease in 
pain from 8.2 at 
baseline to 4.0 at 3 
months (p<0.001). 
Significant decrease in 
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clinical and 
radiological 
evidence of PVI. 
 
sclerosant and 
coil. 
follow-up. VVCS from 8.4 at 
baseline to 3.6 at 3 
months follow-up 
(P<0.001). No VV 
recurrence by 6 
months. 
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Table S2a. Demographics details of the patients in the included studies of effectiveness of 
embolization (age) 
Author 
(date) 
Age 
(years) 
 
Mean SD Range 
Capasso 
1997 
35.2 
 
24-59 
Tarazov 
1997 
32.5 6.3 25-40 
Cordts 
1998 
32.2 6.5 20-43 
Scultetus 
2002£* 
34 
 
24-48 
Venbrux 
2002 
32.3 
 
16-66 
Chung 
2003 
40.1 4.9  
Pieri 
2003 
44.3  36-56 
Kim 
2006 
34 12.5  
Leal Monedero 
2006 
NS   
Richardson 37.5 6.9  
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2006* 
Creton 
2007 
41.5  31-50 
Greiner 
2007 
41  32-65 
Kwon 
2007 
39.1 9 25-64 
Gandini 
2008 
36.9 
 
22-44 
Ratnam # 
2008 
46.3 
 
28-70 
Sukovatykh 
2008 
NS 
  
Tropeano 
2008 
36 
 
19-50 
Asciutto 
2009 
49 11 27-72 
D’Archambeau 
2010 
40.3 
 
20-66 
Tinelli 
2012 
51  43-59 
van der Vleuten 
2012 
41.7 9.6 30-71 
Meneses 38 
 
25-39 
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2013 
 
* Data for whole reported population, not solely those undergoing embolization 
# Data recorded only for first 60 patients of 218 in study 
& Described as mean parity and gravida in 15 parous women of the 19 in study 
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Table S2b. Demographics details of the patients in the included studies of effectiveness of 
embolization (parity) 
Author 
(date) 
Parity 
(Gravida) 
 Mean SD Range % Nulliparous 
Capasso 
1997 
2 (2)&  0(0) to 5(6) 22.2 
Tarazov 
1997 
1.2 (6.5)  0(4) to 2(9) 16.6 
Cordts 
1998 
>2  (>2)  
 
0 
Scultetus 
2002£* 
3.1  2 to 5 
 
Venbrux 
2002 
NS  
  
Chung 
2003 
2.1 1.1  7.7 
Pieri 
2003 
NS    
Kim 
2006 
NS    
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Leal Monedero 
2006 
NS    
Richardson 
2006* 
3.3 1.2   
Creton 
2007 
NS (2.5)  (1 to 4)  
Greiner 
2007 
4  2(2) to 8(8) 0 
Kwon 
2007 
2.4   0 
Gandini 
2008  
 
 
13.1 
Ratnam # 
2008  
 
 
3.3 
Sukovatykh 
2008 
NS  
  
Tropeano 
2008 
0.9(0.9) 0.9 0 to 2 46 
Asciutto 
2009 
NS(2.5)  0 to 7 
 
D’Archambeau 
2010 
NS  
  
Tinelli 
2012 
2.1    
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* Data for whole reported population, not solely those undergoing embolization 
# Data recorded only for first 60 patients of 218 in study 
& Described as mean parity and gravida in 15 parous women of the 19 in study 
 
 
van der Vleuten 
2012 
2.9 1.1 2 to 6  
Meneses 
2013 
3.5  2 to 5 
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Table S3 Quality assessment of case series included in the systematic review of effectiveness of embolization for pelvic congestion syndrome 
Study Ai
m 
Prospe
ctive 
Mu
lti-
cen
ter 
Eligib
ility 
Compa
rable 
pain at 
baselin
e 
Techn
ique 
Other 
interve
ntions 
Outc
omes 
descri
bed 
Vali
d 
outc
ome 
Stati
stics 
Timep
oints 
Los
s to 
foll
ow-
up 
Varia
bility 
Adv
erse 
even
ts 
Conclu
sions 
Conf
licts 
Capasso 
1997 
Y U N N U Y Y N N N/A N U N/A Y Y N 
Tarazov 
1997 
Y U N N Y Y N N N N/A Y U N/A Y Y N 
Cordts 
1998 
Y Y N N Y Y Y U U N/A N U N/A Y Y N 
Scultetus 
2002 
Y U U N Y Y U Y U N N Y N/A Y U N 
Venbrux Y Y U N U Y Y Y Y Y Y Y Y Y Y N 
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2002 
Pieri 
2003 
Y U N N U Y Y N N N Y U N/A Y U N 
Kim 
2006 
Y Y N N U Y Y Y Y Y Y Y Y Y Y None 
Leal 
Moneder
o 2006 
Y U N Y U Y Y N N N N U N/A N Y N 
Richards
on 2006 
Y Y N N U Y U Y Y Y N U Y Y Y N 
Creton 
2007 
Y Y N Y Y Y Y Y Y Y Y Y N/A Y Y N 
Greiner 
2007 
Y Y N N U Y Y Y Y N/A Y Y N Y Y N 
Kwon 
2007 
Y U N N N Y Y Y Y N/A Y Y N Y Y N 
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Gandini 
2008 
Y N N N Y Y Y Y Y Y Y U Y Y Y N 
Ratnam 
2008 
Y Y N N U Y Y N N N Y Y N/A Y Y N 
Tropean
o 2008 
Y Y N N N Y Y Y Y Y Y Y Y Y Y N 
Asciutto 
2009 
Y Y N Y U N Y Y Y Y Y Y Y Y Y None 
D’Archa
mbeau 
2010 
Y Y U U U Y U Y Y U Y Y N/A N Y N 
Tinelli 
2012 
Y U Y Y Y Y Y Y U U Y U Y Y Y N 
Van der 
Vleurten 
2012 
Y Y N N U Y Y Y Y Y Y Y Y N Y None 
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Meneses 
2013  
Y Y N Y Y Y Y Y Y Y Y U Y Y Y N 
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Table S4 Pain scores before and after embolization of pelvic vein incompetence 
 
Time-point (months) 
Study 0 3 6 12 24 36 45 
Venbrux 2002 7.8 4.2b 3.8 b 2.7 b 
   Chung  
2003 
7.8 
(1.2) 
4.5 
(0.9)a 
4.3(0.8) 
a 
3.2 (0.9) 
a    
Kim  
2006 
7.6 
(1.8)      
2.9 
(2.8)d 
Richardson 
2006 
6.6 
(1.9)    
4.0 
(2.8)c   
Creton  
2007 5 1.0c 
 
1.3 c 1.1 c 1.4 c 
 
Gandini 2008 
7.8 
(1.8) 
4.2 
(1.9)a 
3.8 
(0.9)a 
2.7 
(2.8)a 
   Tropeano 2008 8*b 2* b 2.5* b 3* b 
   
Asciutto 2009 
5.2 
(3.5)   2.1 1.5 
1.2 
(0.9)d 
 
Meneses 2013 
8.2 
(0.9) 
4.0 
(1.7)c 
     Key: *median 
P values: a<0.05; b <0.01, c<0.001, d<0.0001, compared to baseline, as reported. 
Supplementary appendix – Search strategies 
 
Search strategy for population and treatment 
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All databases searched from inception to November 2013. 
BIOSIS WEB OF KNOWLEDGE:  
#1   TS=pelvic pain 
#2   TS=chronic pelvic pain 
#3   TS=CPP 
#4   TS=pelvic congestion 
#5   TS=PCS 
#6   TS=congestion syndrome 
#7   TS=pelvic congestion syndrome 
#8   TS=pelvic venous incompetence 
#9   TS=PVI 
#10   TS=ovarian vein incompetence 
#11   TS=((pelvic or pelvis or iliac or ovarian) adj (vein$ or varices)) 
#12   TS=(reflux& or incompetence) 
#13   #12 AND #11 
#14   #3 AND #2 AND #1 
#15   #7 AND #6 AND #5 AND #4 
#16   #9 AND #8 
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#17   #16 OR #15 OR #14 OR #13 OR #10 
#18   TS=treatment 
#19   TS=therap$ 
#20   TS=emboli*ation 
#21   TS=sclerotherapy 
#22   TS=sc*lerotherapy 
#23   TS=ligation 
#24   TS= interventional radiology 
#25   TS=therapeutic emboli*ation 
#26   TS=balloon occlusion 
#27   TS=occulsion 
#28   TS=dilatation 
#29   TS=vasculari*ation 
#30   TS=endovascular surgery 
#31   TS=laparoscopic surgery 
#32   TS=vascular surgical procedure 
#33   TS=vascular surgery 
#34   TS=embolotherapy 
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#35   #34 OR #33 OR #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR   
         #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18  
 
#36   #35 AND #17 
 
BRITISH NURSING INDEX: 
Searched for: all (pelvic congestion) 
 
CINAHL:  
S1   TX=pelvic congestion 
S2   TX=PCS 
S3   TX=congestion syndrome 
S4   TX=pelvic congestion syndrome 
S5   TX=S1 OR S2 OR S3 OR S4 
S6   TX=treatment 
S7   TX=therapy 
S8   TX=emboli*ation 
S9   TX=embolisation 
S10   TX=embolization 
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S11   TX=sclerotherapy 
S12   TX=sc*lerotherapy 
S13   TX=ligation 
S14   TX=balloon occlusion 
S15   TX=occlusion 
S16   TX=dilatation 
S17   TX=vasculari*ation 
S18   TX=endovascular surgery 
S19   TX=laparoscopic surgery 
S20   TX=embolotherapy 
S21   S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16                
         OR S17 OR S18 OR S19 OR S20 
 
S22   S5 AND S21 
 
COCHRANE LIBRARY: 
Pelvic congestion AND PCS search – HTAs 
Pelvic congestion AND PCS search – trials 
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reflux AND vein search - Cochrane reviews 
reflux AND vein search – HTAs 
reflux AND vein search - Other reviews 
reflux AND vein search – trials 
 
DARE: pelvic congestion  
 reflux AND vein 
 
EMBASE: <1980 to 2013 Week 14> 
1     exp Pelvic pain/ or chronic pelvic pain.mp.  
2     CPP.mp.  
3     pelvic congestion.mp.  
4     PCS.mp.  
5     congestion syndrome.mp.  
6     pelvic congestion syndrome.mp.  
7     pelvic venous incompetence.mp.  
8     PVI.mp.  
9     ovarian vein incompetence.mp.  
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10     ((pelvic or pelvis or iliac or ovarian) adj (vein$ or varices)).mp.  
11     (reflux$ or incompetence).mp.  
12     10 and 11  
13     1 and 2  
14     3 and 4  
15     3 and 4 and 5 and 6  
16     7 and 8  
17     9 or 12 or 13 or 15 or 16  
18     treatment.mp.  
19     therap$.mp.  
20     emboli*ation.mp.  
21     exp Sclerotherapy/ or sc*lerotherapy.mp.  
22     ligation.mp. or exp ligation/  
23     interventional radiology.mp. or exp Radiology, Interventional/  
24     exp Embolization, therapeutic/ or balloon occulsion.mp.  
25     occulsion.mp.  
26     dilatation.mp. or exp Dilatation/  
27     vasculari*ation.mp.  
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28     endovascular surgery.mp.  
29     laparoscopic surgery.mp.  
30     exp VascularSurgical Procedures/ or vascular surgery.mp.  
31     embolotherapy.mp. or exp Embolization, therapeutic/  
32     18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31  
33     17 and 32  
 
IMEMR: pelvic congestion  
        reflux vein 
 
IMSEAR: pelvic congestion syndrome 
 
INDEX OF SCIENTIFIC AND TECHNICAL PROCEEDINGS: 
Pelvic congestion syndrome AND vein 
 
LILACS: pelvic AND congestion 
     reflux AND vein 
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MEDION: pelvic AND congestion 
        reflux AND vein 
 
MEDLINE: Ovid MEDLINE(R) <1946 to March Week 1 2013> 
1     exp Pelvic Pain/ or chronic pelvic pain.mp.  
2     CPP.mp.  
3     pelvic congestion.mp.  
4     PCS.mp.  
5     congestion syndrome.mp.  
6     pelvic congestion syndrome.mp.  
7     pelvic venous incompetence.mp.  
8     PVI.mp. 
9     ovarian vein incompetence.mp.  
10     ((pelvic or pelvis or iliac or ovarian) adj (vein$ or varices)).mp.  
11     (reflux$ or incompetence).mp.  
12     10 and 11  
13     1 and 2  
14     3 and 4  
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15     3 and 4 and 5 and 6  
16     7 and 8  
17     9 or 12 or 13 or 15 or 16  
18     treatment.mp.  
19     therap$.mp.  
20     emboli*ation.mp.  
21     exp Sclerotherapy/ or sc*lerotherapy.mp.  
22     ligation.mp. or exp Ligation/  
23     interventional radiology.mp. or exp Radiology, Interventional/  
24     exp Embolization, Therapeutic/ or balloon occulsion.mp.  
25     occulsion.mp.  
26     dilatation.mp. or exp Dilatation/  
27     vasculari*ation.mp.  
28     endovascular surgery.mp.  
29     laparoscopic surgery.mp.  
30     exp Vascular Surgical Procedures/ or vascular surgery.mp.  
31     embolotherapy.mp. or exp Embolization, Therapeutic/  
32     18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31  
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33     17 and 32  
 
PAHO: pelvic AND congestion 
   pelvic AND congestion AND syndrome 
   reflux AND vein 
 
POPLINE: pelvic congestion syndrome 
        pelvic congestion  
          reflux vein 
 
SciELO: pelvic AND congestion AND syndrome 
    reflux AND vein 
    pelvic congestion 
 
WEB OF SCIENCE:  
#1   TS=pelvic pain 
#2   TS=chronic pelvic pain 
#3   TS=CPP 
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#4   TS=pelvic congestion 
#5   TS=PCS 
#6   TS=congestion syndrome 
#7   TS=pelvic congestion syndrome 
#8   TS=pelvic venous incompetence 
#9   TS=PVI 
#10   TS=ovarian vein incompetence 
#11   TS=((pelvic or pelvis or ovarian) adj (vein$ or varices)) 
#12   TS=(9reflux$ or incompetence) 
#13   #12#AND #11 
#14   #3 AND #2 AND #1 
#15   #7 AND #6 AND #5 AND #4 
#16   #9 AND #8 
#17   #16 OR #15 OR #14 OR #13 OR #10 
#18   TS=treatment 
#19   TS=therap$ 
#20   TS=emboli*ation 
#21   TS=sclerotherapy 
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#22   TS=sc*lerotherapy 
#23   TS=ligation 
#24   TS=interventional radiology 
#25   TS=therapeutic emboli*ation 
#26   TS=balloon occlusion  
#27   TS=occlusion 
#28   TS=dilatation 
#29   TS=vasculari*ation 
#30   TS=endovascular surgery 
#31   TS=laparoscopic surgery 
#32   TS=vascular surgical procedure 
#33   TS=vascular surgery 
#34   TS=embolotherapy 
#35   #34 OR #33 OR #32 OR #31 OR #30 OR #29 OR #28 OR #27 OR #26 OR #25 OR 
#24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 
#36   #35 AND #17 
 
WPRIM: pelvic congestion  
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     reflux vein 
 
 
 
